Afami-cel
Adaptimmune Expects To Cut 62% of Staff After Cell Therapy Asset Sale
Adaptimmune; layoffs; cell therapy sale; US WorldMeds; restructuring; biotech workforce reduction; TECELRA; lete-cel; afami-cel; uza-cel
Adaptimmune Prepares for Next FDA Submission Following Success in Pivotal Sarcoma Study
Adaptimmune, FDA submission, sarcoma study, afami-cel, lete-cel, cell therapy, synovial sarcoma, cancer treatment